Skip to content
Menu Close
  • About us
    • Our Journey
    • Board of Directors
    • Leadership
    • Governance
    • Manufacturing
    • R&D
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainability
  • Investors
    • Financials
    • Disclosures under Regulation 46 of SEBI LODR
    • Investor Resources
    • Other Announcements
  • News
    • Press Release
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • About us
    • Our Journey
    • Board of Directors
    • Leadership
    • Governance
    • Manufacturing
    • R&D
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainability
  • Investors
    • Financials
    • Disclosures under Regulation 46 of SEBI LODR
    • Investor Resources
    • Other Announcements
  • News
    • Press Release
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
Menu Close
  •  Global
    • US 
    • India 
    • Europe
    • Latin America
    • ROW
      • Asia
        • Malaysia
      • Australia
      • Me & Africa
      • Russia & CIS
  •  Global
    • US 
    • India 
    • Europe
    • Latin America
    • ROW
      • Asia
        • Malaysia
      • Australia
      • Me & Africa
      • Russia & CIS
  • Global

More results...

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
page
Connect with Us
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global

Glenmark and Bausch Health join together to commercialize RYALTRIS ™ nasal spray in Canada

  • Post author:glenmark2025
  • Post published:March 22, 2021
  • Post category:

Continue ReadingGlenmark and Bausch Health join together to commercialize RYALTRIS ™ nasal spray in Canada

Glenmark divests VWash, a female intimate hygiene wash, to Hindustan Unilever

  • Post author:glenmark2025
  • Post published:March 23, 2020
  • Post category:

Continue ReadingGlenmark divests VWash, a female intimate hygiene wash, to Hindustan Unilever

Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin Tablets, 5 mg and 10 mg

  • Post author:glenmark2025
  • Post published:March 23, 2020
  • Post category:

Continue ReadingGlenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin Tablets, 5 mg and 10 mg

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin and Benzoyl Peroxide Gel, 1%|5%

  • Post author:glenmark2025
  • Post published:March 15, 2019
  • Post category:

Continue ReadingGlenmark Pharmaceuticals receives ANDA approval for Clindamycin and Benzoyl Peroxide Gel, 1%|5%

Glenmark Announces Appointment of Alessandro Riva as CEO of its New Innovation Company

  • Post author:glenmark2025
  • Post published:March 6, 2019
  • Post category:

Continue ReadingGlenmark Announces Appointment of Alessandro Riva as CEO of its New Innovation Company

Glenmark receives ANDA approval for Telmisartan and Hydrochlorothiazide Tablets USP

  • Post author:glenmark2025
  • Post published:March 5, 2019
  • Post category:

Continue ReadingGlenmark receives ANDA approval for Telmisartan and Hydrochlorothiazide Tablets USP

Glenmark Pharmaceuticals Announces Presentation of New Subtype Analysis of GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the American Academy of Dermatology Annual Meeting

  • Post author:glenmark2025
  • Post published:March 4, 2019
  • Post category:

Continue ReadingGlenmark Pharmaceuticals Announces Presentation of New Subtype Analysis of GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the American Academy of Dermatology Annual Meeting

Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Spray, 0.05%

  • Post author:glenmark2025
  • Post published:March 27, 2018
  • Post category:

Continue ReadingGlenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Spray, 0.05%

Glenmark Pharmaceuticals Presents New Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis at the AAAAI/WAO Joint Congress

  • Post author:glenmark2025
  • Post published:March 6, 2018
  • Post category:

Continue ReadingGlenmark Pharmaceuticals Presents New Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis at the AAAAI/WAO Joint Congress
  • Go to the previous page
  • 1
  • 2
  • 3
  • 4
  • 5

Glenmark Pharmaceuticals Ltd. is a research‐led, global pharmaceutical company, having a presence across Branded, Innovative, and Generics segments with a focus on therapeutic areas of respiratory, dermatology and oncology

Linkedin-in Instagram Youtube

About us

  • Our Journey
  • Board of Directors
  • Leadership
  • Governance
  • Manufacturing
  • R&D

Innovation

  • Overview
  • Pipeline
  • Partnerships

Products

  • Portfolio
  • Top Brands

Responsibility

  • Corporate Social Responsibility
  • Sustainability

Investors

  • Financials
  • Disclosures under Regulation 46
    of SEBI LODR
  • Investor Resources
  • Other announcements

News

  • Press Release
  • Media Library

Careers

  • Life at Glenmark
  • Glenmark Centre for Learning
Join Us

CAUTION NOTICE REGARDING FRAUDULENT RECRUITMENT

This is to notify to the public that certain unscrupulous persons, purporting to be part of and/or being authorised by the human resources department of Glenmark Pharmaceuticals Limited (“Glenmark”) are fraudulently offering jobs via certain websites/or through telephone calls, SMS or fake letters and asking the prospective job aspirants to appear for a face-to-face interview for a job opening with Glenmark and/or to pay a fee for securing a job with Glenmark. We wish to caution the public that Glenmark does not collect any monies or any other valuables as a pre or post-employment requirement.

Click Here to Know More        Click Here to Join Us

Download Factsheet
  • Privacy Portal
  • Terms & Conditions
  • Report a Concern
  • Report an Adverse Event
  • Investigator Initiated Trials
© 2026 Glenmark Pharmaceuticals Ltd. All Rights Reserved.
  • About Us
  • Innovation
  • Products
  • Responsibility
  • Investors
  • News
  • Careers
  • Terms & Conditions
  • Report a Concern
  • Report an Adverse Event
  • Investigator Initiated Trials
  • Privacy Portal
Download Factsheet
Linkedin-in Instagram Youtube
© 2026 Glenmark Pharmaceuticals Ltd.
All Rights Reserved.
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global
Type your search

CAUTION NOTICE REGARDING FRAUDULENT RECRUITMENT

This is to notify to the public that certain unscrupulous persons, purporting to be part of and/or being authorised by the human resources department of Glenmark Pharmaceuticals Limited (“Glenmark”) are fraudulently offering jobs via certain websites/or through telephone calls, SMS or fake letters and asking the prospective job aspirants to appear for a face-to-face interview for a job opening with Glenmark and/or to pay a fee for securing a job with Glenmark. We wish to caution the public that Glenmark does not collect any monies or any other valuables as a pre or post-employment requirement.

Click Here to Know More        Click Here to Join Us